Credit Suisse’s Genocea Biosciences, Inc. GNCA Stock Holding History

Credit Suisse’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,821	Closed	-$32K	–	4240
2018 Q1	$32K	Buy	+3,821	New	+$31.7K	﹤0.01%	3914
2017 Q4	–	Sell	-2,444	Closed	-$28K	–	4319
2017 Q3	$28K	Buy	+2,444	New	+$92.8K	﹤0.01%	4155
2016 Q3	–	Sell	-7,208	Closed	-$236K	–	4343
2016 Q2	$236K	Buy	+7,208	New	+$264K	﹤0.01%	3795
2016 Q1	–	Sell	-4,536	Closed	-$192K	–	4416
2015 Q4	$192K	Buy	+4,536	New	+$216K	﹤0.01%	3907
2015 Q2	–	Sell	-1,514	Closed	-$144K	–	4702
2015 Q1	$144K	Buy	+1,514	New	+$107K	﹤0.01%	4162

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's GNCA Position: Q2 2018 in Review

Credit Suisse sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 3,821 shares — an estimated $32K sold.

Credit Suisse first reported a position in GNCA in Q1 2015 and held it in 5 quarters. The position peaked at $236K in Q2 2016. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

Credit Suisse reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
Credit Suisse sold 3,821 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $32K.
Credit Suisse first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 5 quarters.
Credit Suisse's Genocea Biosciences, Inc. position peaked at $236K in Q2 2016.
54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.